AstraZeneca’s breast cancer drug Etcamah did not meet its main goal in a late-stage trial. The drug showed only a numerical improvement when combined with palbociclib. This marks a setback for the recently approved treatment, which received accelerated approval. U.S.-listed shares of AstraZeneca experienced a decline in aftermarket trading. Trial data will be shared by the company in due course.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.